Depomed Inc. granted an exclusive license to Solvay Pharmaceuticals Inc. for North American rights to DM-1796 (formerly Gabapentin GR) in pain indications. The drug - an extended-release version of the active ingredient in Pfizer Inc.'s marketed seizure and pain drug, Neurontin - is in Phase III trials for postherpetic neuralgia (PHN). (BioWorld Today) Read More